Cancer Spit Test Device Market
In recent years, the world has experienced an increase in the number of chronically diseased patients, and specifically the number of cancer patients. For that reason, firms within the healthcare, technology, and testing industry have focused their efforts on developing efficient methods for the detection of diseases. In the field of cancer testing, a method that increasingly gains popularity is saliva testing. The aim of this type of test is to establish whether the is a presence or absence of mutated extra-cellular DNA and RNA within the saliva. The reason why this testing is superior to others in terms of accuracy of mutation detection is that the tumor cells shed DNA and RNA into circulation after which they appear in saliva. The industry makes use of testing kits, swabs, cassettes, and alternative devices used for the detection of drugs, infection, or disease in patients. On the basis of molecular biology methods for detection, testing kits are divided into ELISA, PCR, immunoassay, and enzymatic assays among other techniques for molecular testing.
The Cancer Spit Test Device Market is projected to reach US$1,019.38 million by 2031 from US$506.76 million in 2021, growing with a CAGR of 9.7% during the forecast period from 2022 to 2031.
Cancer Spit Test Device Market Growth and Trend
The trend of increasing cancer-related cases globally and the increasing investment of funds for healthcare and specifically, disease detection and prevention, are expected to exert a positive influence on the Cancer Spit Test Device market.
Cancer Spit Test Device Market Segmentation
The Cancer Spit Test Device Market is segmented on the basis of product type, site of collection, application, age group, method of collection, end-user, and distribution channel. According to the type of product, the market is divided into saliva collection kits, fluid-specific devices, oral swabs, bar-code labels, saliva cryostorage boxes, and others. The saliva collection kits are projected to dominate the market in 2022, due to the increasing numbers of cancer cases globally, as well as the popularity of POCT devices.
Based on the site of collection, the Cancer Spit Test Device industry differentiates between sub-mandibular/sub-lingual gland, parotid gland, and minor salivary gland. Expectations for the growth of this segment are due to the rising demand for sub-mandibular/sublingual glands, as a result of expansion in healthcare expenditure and increased cooperation from patients. Additionally, on the basis of application, the market is divided into liver-lung cancer, breast cancer, colon and rectal cancer, prostate cancer, pancreatic cancer, oral cancer, thyroid cancer, endometrial cancer, kidney cancer, leukemia, melanoma, non-Hodgkin lymphoma, and others. Due to the rising number of cases concerning liver cirrhosis and chronic diseases, it is projected that the liver-lung cancer segment would have the leading position within the industry. In terms of age group, the market is split into adult and pediatrics segments, where the former segment is projected to dominate the market, due to the rising geriatric population all over the world. Based on the method of collection, the market segments are passive drool, oral swab, and others types. The leadership position is expected to be held by the passive drool segment, because of the non-intrusive nature of the method and its ease of use. On the basis of the end-use industry, the market is divided into hospitals, diagnostic laboratories, oncology specialty clinics, cancer research institutes, and others segments, where, as expected the largest number of sales is expected to be generated from hospitals.
Finally, based on the distribution channel, the different segments are direct tender, retail sales, or others, and projections are positive towards the dominance of the direct tender segment, as there are many industry-leading firms.
Cancer Spit Test Device Market Regional Analysis
The number of cancer cases, as well as the investment in healthcare, are crucial factors affecting the difference in regional expansion of the Cancer Spit Test Device industry. The North American region has been dominating in recent years, as a result of the rise of chronic diseases within the population. More specifically, the U.S. had the biggest contribution towards the growth of the market, due to the rising geriatric population. On the other hand, the Asia Pacific region is projected to experience the highest growth rate out of all regions between 2022 and 2031, due to the increasing number of cancer cases. Out of the countries within the region, China is expected to develop the industry the most, because of the availability of disposable income of the population. Additionally, the European region is also forecasted to grow its share of the market, due to the innovations in technology that are expected to be adopted in the future. As many large providers of such are based in Germany, the country has a dominant position within the Cancer Spit Test Device industry.
Cancer Spit Test Device Market Share and Competition
The major players operating in the Cancer Spit Test Device industry are DNA Genotek, Salimetrics, LLC, PeriRx, Color Health, Inc., SARSTEDT AG. Co. KG, Miraclean Technology Co., Ltd., Agilent Technologies, Inc., Illumina, Inc., QIAGEN, Thermo Fisher Scientific Inc., Abbott, BD, Biocartis, bioMérieux SA, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, Oasis Diagnostics Corporation, Canvas, and others.
Report Highlights
• Historical Revenue and Unit Sales Volume Data (2010 - 2020)
• Forecast Revenue and Unit Sales Volume Data (2022 - 2031)
• Price trend and analysis
• Segment based revenue and unit sales data (2010 - 2031)
• Import/Export Analysis
• Competitive Analysis and Company Profiles
• Product analysis and Strategic framework
Industry segmentation and Revenue Breakdown
Product Type Analysis (Revenue, USD Million, 2022 - 2031)
• Saliva collection kits
• Fluid specific devices
• Oral swab
• Bar-code labels
• Saliva cryostorage box
Site of collection Analysis (Revenue, USD Million, 2022 - 2031)
• Sub-mandibular/sub-lingual gland
• Parotid gland
• Minor salivary gland
Application Type Analysis (Revenue, USD Million, 2022 - 2031)
• Liver-lung cancer
• Breast cancer
• Colon and rectal cancer
• Prostate cancer
• Pancreatic cancer
• Oral cancer
• Thyroid cancer
• Endometrial cancer
• Kidney cancer
• Leukemia
• Melanoma
• Non-Hodgkin lymphoma
Age group Analysis (Revenue, USD Million, 2022 - 2031)
• Adults
• Pediatrics
Method of collection Analysis (Revenue, USD Million, 2022 - 2031)
• Passive drool
• Oral swab
End-user Analysis (Revenue, USD Million, 2022 - 2031)
• Hospitals
• Diagnostic laboratories
• Oncology specialty clinics
• Cancer research institutes
Distribution channel Analysis (Revenue, USD Million, 2022 - 2031)
• Direct tender
• Retail sales
Country Analysis (Revenue, USD Million, 2022 - 2031)
• U.S.
• Canada
• Mexico
• Brazil
• Argentina
• Rest of South America
• Germany
• France
• Italy
• U.K.
• Belgium
• Spain
• Russia
• Turkey
• Netherlands
• Switzerland
• Rest of Europe
• Japan
• China
• India
• South Korea
• Australia
• Singapore
• Malaysia
• Thailand
• Indonesia
• Philippines
• Rest of Asia-Pacific
• U.A.E
• Saudi Arabia
• Egypt
• South Africa
• Israel
• Rest of the Middle East and Africa
Cancer Spit Test Device Market Companies
• DNA Genotek
• Salimetrics, LLC
• PeriRx
• Color Health, Inc.
• SARSTEDT AG. Co. KG
• Miraclean Technology Co., Ltd.
• Agilent Technologies, Inc.
• llumina, Inc.
• QIAGEN
• Thermo Fisher Scientific Inc.
• Abbott
• BD
• Biocartis
• bioMérieux SA
• Siemens Healthcare GmbH
• F. Hoffmann-La Roche Ltd
• Oasis Diagnostics Corporation
• Canvaz
Request Custom Proposal to get a detailed study on specific product segment or country or in case of
a requirement from the relative industry.
Fill the sample request form below or email directly to david@marketdecipher.com
